In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the
world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

PURPOSE BRAF V600E mutations are rarely associated with objective responses to the
BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of …

The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis,
pathologic staging, surgical management, perioperative treatment, surveillance …

Colorectal cancer (CRC) is often diagnosed at an advanced stage when tumor cell
dissemination has taken place. Chemo-and targeted therapies provide only a limited …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

The most recent version of the European Society for Medical Oncology (ESMO) consensus
guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …